What the insurance change actually covers, and when
On 14 November 2026 China's National Healthcare Security Administration published the 2026 national basic medical insurance drug list. Relmacabtagene autoleucel (trade name Carteyva, developed by JW Therapeutics) became the first CAR-T therapy included in the national list, and remains the only one there. Its list price falls from ¥1,290,000 per infusion to below ¥300,000. The new price applies from 1 January 2027; until then the previous arrangement stands.
Three limits matter for planning. First, the listing covers three indications only, each in the third-line setting: relapsed or refractory large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Second, reimbursement applies to people covered by Chinese basic medical insurance. Insured patients may see out-of-pocket drug costs fall below ¥100,000 after reimbursement, but that figure describes insured residents, not visitors. Third, ¥300,000 is the medicine price. It does not include leukapheresis, lymphodepleting chemotherapy, hospital stay, intensive care, or management of complications, which are billed separately.
For an international patient the practical position is unchanged: no Chinese insurance, so the drug is paid at the listed price and hospital charges are additional. Ask the treating centre for a written estimate covering the whole admission, not the drug alone.
The three lymphoma types in the approved indications
Large B-cell lymphoma is the most familiar CAR-T target. Patients become candidates when the disease has relapsed after, or failed to respond to, at least two prior lines of systemic therapy, and when a further standard salvage regimen is unlikely to produce a durable response. Diffuse large B-cell lymphoma and high-grade B-cell lymphomas fall within this group; the treating haematologist maps your specific pathology onto the approved wording.
Follicular lymphoma is slower-growing, and the CAR-T indication sits after multiple prior lines in patients whose disease keeps returning. Mantle cell lymphoma is a separate entity with its own biology and its own prior-treatment history. In all three, "third line" is a count of previous systemic treatments, not a stage. A patient who has had two lines may be at the threshold; a patient who has had four is not disqualified by the number alone, but the approved label and the centre's protocol govern.
Bring the pathology report, the treatment history with dates and regimens, and the most recent imaging. The clinician needs to confirm the diagnosis, the number of prior lines, and whether the disease is currently active enough to warrant cellular therapy.
Who may qualify and who may not
Eligibility is a clinical judgement made by the treating team, and the label is only the starting point. Haematologists generally weigh disease control, organ function, infection status and the patient's ability to tolerate the procedure.
Performance status is central. A patient who is largely bedbound is unlikely to tolerate lymphodepletion and the days after infusion. Heart, lung, liver and kidney function are reviewed because the conditioning chemotherapy and complications place demands on them. Active or uncontrolled infection is normally addressed before collection. A history of prior CAR-T therapy, or of allogeneic transplant, raises questions the team must answer individually rather than by rule.
Some patients are redirected. If the disease burden is very high or pressing, the team may prefer bridging therapy first. If the lymphoma has transformed or the pathology is uncertain, a pathology review may be requested. If the patient is stable and well, watchful waiting may be discussed instead of immediate cellular therapy.
No article can tell you whether you qualify. Ask the centre directly which of your prior treatments count toward the line requirement, and what would make you ineligible.
What the evidence shows, and what it does not
CAR-T therapy for relapsed B-cell lymphoma is supported by registered trials and by real-world series, and the general finding is that a meaningful proportion of heavily pretreated patients achieve durable remissions. The exact response and cure figures differ by product, by lymphoma type, and by how sick patients were at infusion. This guide deliberately avoids quoting percentages, because a number taken from one trial does not predict your outcome.
Ask the treating team which published data they rely on for your lymphoma subtype, and whether those data come from the registration trial or from their own and other centres' real-world experience. Ask how they define response, when they assess it, and what they offer if the disease progresses after CAR-T.
Be cautious with any clinic that presents a single success rate as a guarantee. Cellular therapy carries real risks, and the honest conversation is about probability and alternatives, not certainty.
Where CAR-T is delivered in China
CAR-T is a restricted clinical technology in China, which means centres must hold the relevant technical qualification and be able to run the full pathway: leukapheresis to collect T cells, bridging treatment if needed, lymphodepleting chemotherapy, infusion, and close monitoring with intensive care backup. Not every hospital that treats lymphoma offers it.
When you approach a centre, ask whether it holds the qualification for the specific product and indication, whether apheresis and the cell-processing logistics are handled in-house or through a partner laboratory, and what critical-care support is available on site. Ask how many CAR-T infusions the team has performed and for which lymphoma types. These are reasonable questions, and a well-organised centre will answer them.
China has approved multiple CAR-T products, so availability of a particular product at a particular hospital is a separate question from national approval. Confirm product availability in writing before making travel plans.
The treatment pathway and the risks that need watching
The pathway usually begins with disease assessment and T-cell collection, followed by a waiting period while the product is manufactured. Many patients receive bridging therapy during that interval to keep the lymphoma controlled. Before infusion, lymphodepleting chemotherapy prepares the body. After infusion, the patient stays under close observation.
Two complications dominate the post-infusion period. Cytokine release syndrome produces fever, low blood pressure and breathing difficulty, and is managed with supportive care and targeted medication according to severity. Immune effector cell-associated neurotoxicity syndrome causes confusion, word-finding difficulty, headache or seizures and requires prompt reporting. Both can become serious, which is why monitoring is close and why the team needs a clear escalation plan.
Other risks include prolonged low blood counts, infection, and effects on antibody levels that may require replacement therapy. Ask the team how they grade and treat these events, what triggers intensive care, and what follow-up and vaccination guidance they give after discharge. Recovery varies widely between patients, so treat any fixed timeline with caution.
What changes after January 2027, and how foreign patients should plan
From 1 January 2027, insured Chinese residents with one of the three listed indications may access relmacabtagene autoleucel at the reduced list price, with reimbursement reducing their share further. Expect demand for assessment and apheresis slots to rise, and ask the centre how it schedules patients and how it prioritises urgent cases. Do not assume the new price is available before that date.
For international patients, the route is self-pay. The drug is priced at the listed amount, and hospital charges for collection, conditioning, admission, monitoring and any intensive care are additional. Ask for a written estimate that separates the medicine from hospital services and states what happens if complications extend the stay. Ask whether a deposit is required and how it is handled.
Start with a records-based review rather than travel. Send the pathology report, treatment history, recent imaging and a short summary of the patient's current condition. The centre can then say whether the indication fits and what further tests it needs. An initial enquiry through ChinaSpecialistCare is free and does not commit you to a proxy consultation; the hospital alone decides suitability and acceptance. You can read more about the procedure on our CAR-T cell therapy page and about blood cancer care on the haematology specialty page.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
